456 related articles for article (PubMed ID: 31152489)
1. The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tp-e interval, 5-year sudden cardiac death risk score in hypertrophic cardiomyopathy patients.
Riza Demir A; Celik Ö; Sevinç S; Uygur B; Kahraman S; Yilmaz E; Cemek M; Onal Y; Erturk M
Ann Noninvasive Electrocardiol; 2019 Sep; 24(5):e12672. PubMed ID: 31152489
[TBL] [Abstract][Full Text] [Related]
2. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
[TBL] [Abstract][Full Text] [Related]
3. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C
Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597
[TBL] [Abstract][Full Text] [Related]
4. Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function.
Mentias A; Raeisi-Giglou P; Smedira NG; Feng K; Sato K; Wazni O; Kanj M; Flamm SD; Thamilarasan M; Popovic ZB; Lever HM; Desai MY
J Am Coll Cardiol; 2018 Aug; 72(8):857-870. PubMed ID: 30115224
[TBL] [Abstract][Full Text] [Related]
5. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
[TBL] [Abstract][Full Text] [Related]
6. The Value of Myocardial Fibrosis Parameters Derived from Cardiac Magnetic Resonance Imaging in Risk Stratification for Patients with Hypertrophic Cardiomyopathy.
Yu T; Cai Z; Yang Z; Lin W; Su Y; Li J; Xie S; Shen J
Acad Radiol; 2023 Sep; 30(9):1962-1978. PubMed ID: 36604228
[TBL] [Abstract][Full Text] [Related]
7. Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study.
Greulich S; Seitz A; Herter D; Günther F; Probst S; Bekeredjian R; Gawaz M; Sechtem U; Mahrholdt H
Eur Heart J Cardiovasc Imaging; 2021 Jun; 22(7):732-741. PubMed ID: 33458753
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy.
He D; Ye M; Zhang L; Jiang B
Heart Lung; 2018; 47(2):122-126. PubMed ID: 29174363
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
[TBL] [Abstract][Full Text] [Related]
10. Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy.
McLELLAN AJ; Ellims AH; Prabhu S; Voskoboinik A; Iles LM; Hare JL; Kaye DM; Macciocca I; Mariani JA; Kalman JM; Taylor AJ; Kistler PM
J Cardiovasc Electrophysiol; 2016 May; 27(5):571-80. PubMed ID: 26840595
[TBL] [Abstract][Full Text] [Related]
11. Entropy of left ventricular late gadolinium enhancement and its prognostic value in hypertrophic cardiomyopathy a new CMR assessment method.
Zhao X; Jin F; Wang J; Zhao X; Wang L; Wei H
Int J Cardiol; 2023 Feb; 373():134-141. PubMed ID: 36395920
[TBL] [Abstract][Full Text] [Related]
12. Late gadolinium enhancement is common in patients with hypertrophic cardiomyopathy and no clinical risk factors for sudden cardiac death: A single center experience.
Lyons KS; Dixon LJ; Johnston N; Noad R; Hamilton A; McKeag N; Horan P
Cardiol J; 2014; 21(1):29-32. PubMed ID: 23990187
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score.
Todiere G; Nugara C; Gentile G; Negri F; Bianco F; Falletta C; Novo G; Di Bella G; De Caterina R; Zachara E; Re F; Clemenza F; Sinagra G; Emdin M; Aquaro GD
Am J Cardiol; 2019 Oct; 124(8):1286-1292. PubMed ID: 31447011
[TBL] [Abstract][Full Text] [Related]
14. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.
Avanesov M; Münch J; Weinrich J; Well L; Säring D; Stehning C; Tahir E; Bohnen S; Radunski UK; Muellerleile K; Adam G; Patten M; Lund G
Eur Radiol; 2017 Dec; 27(12):5136-5145. PubMed ID: 28616729
[TBL] [Abstract][Full Text] [Related]
15. The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study.
Weissler-Snir A; Hindieh W; Spears DA; Adler A; Rakowski H; Chan RH
J Cardiovasc Electrophysiol; 2019 May; 30(5):651-657. PubMed ID: 30680853
[TBL] [Abstract][Full Text] [Related]
16. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.
Bogarapu S; Puchalski MD; Everitt MD; Williams RV; Weng HY; Menon SC
Pediatr Cardiol; 2016 Apr; 37(4):663-73. PubMed ID: 26833321
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
Green JJ; Berger JS; Kramer CM; Salerno M
JACC Cardiovasc Imaging; 2012 Apr; 5(4):370-7. PubMed ID: 22498326
[TBL] [Abstract][Full Text] [Related]
18. [Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].
Li WX; Liu LW; Wang J; Zuo L; Yang F; Kang N; Lei CH
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1033-1038. PubMed ID: 29325362
[No Abstract] [Full Text] [Related]
19. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.
Weng Z; Yao J; Chan RH; He J; Yang X; Zhou Y; He Y
JACC Cardiovasc Imaging; 2016 Dec; 9(12):1392-1402. PubMed ID: 27450876
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Prognosis of Presence and Location of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Imaging in Patients with Hypertrophic Cardiomyopathy: a Single-Center Cohort Study.
Li X; Lai L; Luo R; Yang H; Ma H; Yang Z; Zhao S; Su W; Hua W
J Cardiovasc Transl Res; 2021 Oct; 14(5):1001-1016. PubMed ID: 33629154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]